Opaxio and Pixantrone are being used as a maintenance drug for Ovarian Cancer and as a sensitize for Esophageal Cancer and for aggressive Hodgkin Lymphoma.
According to Cell Therapeutics' website they "Our cancer drug development pipeline includes a biologically enhanced taxane, a new compound designed to treat cancers normally treated with anthracyclines, and a DNA minor groove binding agent—each of which has the potential to treat a variety of cancer types."
They also have a variety of clinical trials.
Ovarian Cancer Trials (Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer)
Glioblastoma Multiforme Anaplastic Glioma Trials
Breast Cancer-HER2 Negative Trial
The PIX-R TRIAL is a randomized multicenter study comparing pixantrone + rituximab with gemcitabine + rituximab in patients with Diffuse Large B-Cell Lymphoma (DLBCL) who have relapsed after therapy with CHOP-R or an equivalent regimen and are ineligible for stem cell transplant